hla a2 antigen

Summary

Summary: Human histocompatibility (HLA) surface antigen encoded by the A locus on chromosome 6. The HLA-A2 antigen is associated with recognition of the INFLUENZA A VIRUS.

Top Publications

  1. pmc Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
    Y Kawakami
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 91:6458-62. 1994
  2. pmc The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL
    M R Wills
    Department of Medicine, University of Cambridge Clinical School, United Kingdom
    J Virol 70:7569-79. 1996
  3. ncbi Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer
    Nobuaki Suzuki
    Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Int J Cancer 98:45-50. 2002
  4. ncbi HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice
    Yutaka Motomura
    Cancer Immunotherapy Project, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa 277 8577, Japan
    Int J Oncol 32:985-90. 2008
  5. ncbi Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids
    Y H Ding
    Department of Molecular and Cellular Biology, Harvard University, Howard Hughes Medical Institute, Cambridge, Massachusetts 02138, USA
    Immunity 8:403-11. 1998
  6. ncbi Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain
    Fumiyoshi Okano
    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 8:2851-5. 2002
  7. pmc EphA2 as a glioma-associated antigen: a novel target for glioma vaccines
    Manabu Hatano
    Department of Neurological Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Neoplasia 7:717-22. 2005
  8. pmc Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences
    C Brander
    AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Virol 73:10191-8. 1999
  9. ncbi HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides
    M L Wei
    Department of Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina 27710
    Nature 356:443-6. 1992
  10. ncbi Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance
    Alfred Zippelius
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research and Multidisciplinary Oncology Center, University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cancer Res 64:2865-73. 2004

Detail Information

Publications299 found, 100 shown here

  1. pmc Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
    Y Kawakami
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 91:6458-62. 1994
    ....
  2. pmc The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL
    M R Wills
    Department of Medicine, University of Cambridge Clinical School, United Kingdom
    J Virol 70:7569-79. 1996
    ....
  3. ncbi Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer
    Nobuaki Suzuki
    Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Int J Cancer 98:45-50. 2002
    ..Positive peptide profiles varied among patients. These results may provide a scientific basis for a new kind of cancer immunotherapy, namely, a CTL precursor-oriented peptide vaccine, for pancreatic cancer patients...
  4. ncbi HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice
    Yutaka Motomura
    Cancer Immunotherapy Project, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa 277 8577, Japan
    Int J Oncol 32:985-90. 2008
    ..The results of this study suggested that IFA is one of the indispensable adjuvants for peptide-based immunotherapy, and that the immunological effect of peptide vaccines depends on the dose of peptide injected...
  5. ncbi Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids
    Y H Ding
    Department of Molecular and Cellular Biology, Harvard University, Howard Hughes Medical Institute, Cambridge, Massachusetts 02138, USA
    Immunity 8:403-11. 1998
    ..The existence of a structurally similar diagonal binding mode for TCRs favors mechanisms based on the formation of geometrically defined supramolecular assemblies for initiating signaling...
  6. ncbi Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain
    Fumiyoshi Okano
    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 8:2851-5. 2002
    ..Interleukin 13 receptor alpha2-chain (IL-13Ralpha2) has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme. Here we report the identification of a CTL epitope derived from the IL-13Ralpha2...
  7. pmc EphA2 as a glioma-associated antigen: a novel target for glioma vaccines
    Manabu Hatano
    Department of Neurological Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Neoplasia 7:717-22. 2005
    ..Taken together, these data suggest that EphA2883-891 may be an attractive antigen epitope for molecularly targeted glioma vaccines...
  8. pmc Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences
    C Brander
    AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Virol 73:10191-8. 1999
    ..These data suggest that escape from this immunodominant CTL response is not frequently accomplished by changes in the epitope flanking sequences...
  9. ncbi HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides
    M L Wei
    Department of Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina 27710
    Nature 356:443-6. 1992
    ..To our knowledge, this is the first report of the isolation of a fragment of a eukaryotic signal peptide generated in vivo...
  10. ncbi Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance
    Alfred Zippelius
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research and Multidisciplinary Oncology Center, University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cancer Res 64:2865-73. 2004
    ..We show that both the lymph node and the tumor environments blunt T-cell effector functions and offer a rationale for the failure of tumor-specific responses to effectively counter tumor progression...
  11. ncbi Structure of the complex between human T-cell receptor, viral peptide and HLA-A2
    D N Garboczi
    Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA
    Nature 384:134-41. 1996
    ..A broadly applicable binding mode has implications for the mechanism of repertoire selection and the magnitude of alloreactions...
  12. pmc HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice
    S Pascolo
    Institut Pasteur, Département SIDA Rétrovirus, Unité d Immunité Cellulaire Antivirale, 75724 Paris Cedex 15, France
    J Exp Med 185:2043-51. 1997
    ..1-restricted immunodominant epitope in humans. Such mice might constitute a versatile animal model for the study of HLA-A2.1-restricted CTL responses of vaccine interest...
  13. ncbi Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
    C Yee
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington, Seattle 98109, USA
    J Immunol 162:2227-34. 1999
    ....
  14. ncbi Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution
    M A Saper
    Department of Biochemistry and Molecular Biology, Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138
    J Mol Biol 219:277-319. 1991
    ..A possible role for beta 2m in stabilizing permissible peptide complexes during folding and assembly is presented...
  15. pmc Identification of a crucial energetic footprint on the alpha1 helix of human histocompatibility leukocyte antigen (HLA)-A2 that provides functional interactions for recognition by tax peptide/HLA-A2-specific T cell receptors
    B M Baker
    Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138 USA
    J Exp Med 193:551-62. 2001
    ..These results show that for Tax/HLA-A2-specific TCRs, there is a location on the central portion of the alpha1 helix that provides interactions crucial to their function with the MHC molecule...
  16. ncbi The use of chimeric A2K(b) tetramers to monitor HLA A2 immune responses in HLA A2 transgenic mice
    E M Choi
    Molecular Immunology Group, Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, OX3 9DS Headington, Oxford, UK
    J Immunol Methods 268:35-41. 2002
    ..The use of these novel staining reagents will allow efficient comparison of vaccination strategies and rapid identification of novel CTL epitopes in A2 transgenic mice...
  17. ncbi Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules
    M H Newberg
    Department of Microbiology, University of Virginia, Charlottsville, 22908, USA
    J Immunol 156:2473-80. 1996
    ....
  18. ncbi The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients
    Xiao Ying Shang
    Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People s Republic of China
    Clin Cancer Res 10:6946-55. 2004
    ....
  19. pmc The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design
    Marcus Altfeld
    Partners AIDS Research Center, Massachusetts General Hospital, 149 13th St, Boston, MA 02129, USA
    J Virol 79:5000-5. 2005
    ....
  20. ncbi Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide
    Yuji Sato
    First Department of Surgery, Hokkaido University School of Medicine, N15 W7 Sapporo, Hokkaido 060 8638, Japan
    Cancer Sci 94:802-8. 2003
    ..These results encourage further development of peptide-based immunotherapy for GC patients...
  21. ncbi Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity
    A Propato
    Foundazione Andrea Cesalpino, Dipartimento di Medicina Interna, , Policlinico Umberto I, Rome, Italy
    Hum Immunol 62:561-76. 2001
    ..In conclusion, the analysis of HIV-specific cellular responses in these individuals may help define clear correlates of protective immunity in HIV infection...
  22. ncbi Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice
    Huseyin Firat
    Genethon III, CNRS URA 1923, 1 bis rue de l Internationale, BP 60, 91002 Evry Cedex, France
    Int Immunol 14:925-34. 2002
    ..1/K(b) mice. These observations provide the molecular bases accounting for the fact that HHD mice represent the most versatile animal model currently available for preclinical studies of HLA-A2.1-restricted CTL responses...
  23. ncbi Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen
    Jun Lu
    Department of Immunology, Mayo Graduate School, and Mayo Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:5807-12. 2002
    ..These results underline the importance of demonstrating antitumor reactivity of peptide-induced CTLs for the selection of epitopes destined to become immunotherapeutic for prostate cancer...
  24. ncbi Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma
    Galina V Yamshchikov
    Department of Surgery, University of Virginia, Charlottesville, 22908, USA
    J Immunol 174:6863-71. 2005
    ....
  25. ncbi Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides
    A K Sewell
    Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, GB
    Eur J Immunol 27:2323-9. 1997
    ..We found no evidence that CTL exposed to an antagonist received a functionally negative signal since these CTL retained an unimpaired capacity to lyse targets bearing wild-type peptide...
  26. ncbi A fractal clonotype distribution in the CD8+ memory T cell repertoire could optimize potential for immune responses
    Yuri N Naumov
    Department of Pathology, University of Massachusetts Medical School, Worchester, MA 01655, USA
    J Immunol 170:3994-4001. 2003
    ..Self similarity, power laws, and recursive mapping algorithms are associated with fractal systems. Thus, Ag-specific memory CD8 T cell repertoires can be considered as fractal, which could indicate optimized flexibility and robustness...
  27. ncbi Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers
    Naotake Tsuda
    Departments of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    J Immunother 27:60-72. 2004
    ....
  28. ncbi Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual
    T Harrer
    Department of Medicine III with Institute of Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    J Immunol 161:4875-81. 1998
    ..In addition, they demonstrate that Ag processing can allow for presentation of overlapping epitopes in the same infected cell, which can be affected quite differently by sequence variation...
  29. pmc Structural and kinetic basis for heightened immunogenicity of T cell vaccines
    Ji Li Chen
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    J Exp Med 201:1243-55. 2005
    ....
  30. ncbi The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain
    M A Purbhoo
    University of Oxford, Nuffield Department of Clinical Medicine, Level 7, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom
    J Biol Chem 276:32786-92. 2001
    ..These reagents may prove useful in circumventing undesirable activation-related perturbation of intracellular processes when pMHC multimers are used to phenotype antigen-specific CD8+ lymphocytes...
  31. ncbi Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical
    Y H Ding
    Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA
    Immunity 11:45-56. 1999
    ..The lack of correlation between structural changes and the type of T cell signals induced provides direct evidence that different signals are not generated by different ligand-induced conformational changes in the alphabeta TCR...
  32. ncbi Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma
    Hiroyuki Komori
    Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Honjo, Japan
    Clin Cancer Res 12:2689-97. 2006
    ..In addition, we used HLA-A2.1 (HHD) transgenic mice to identify the HLA-A2 (A*0201)-restricted GPC3 epitopes to expand the applications of GPC3-based immunotherapy to the HLA-A2+ HCC patients...
  33. pmc Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection
    P J Goulder
    Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    J Exp Med 193:181-94. 2001
    ..This finding is an important consideration in vaccine design and in the evaluation of vaccine candidates...
  34. ncbi A structural basis for immunodominant human T cell receptor recognition
    Guillaume B E Stewart-Jones
    Division of Structural Biology, The Henry Wellcome Building for Genomic Medicine, Roosevelt Drive, Oxford OX3 7BN, UK
    Nat Immunol 4:657-63. 2003
    ..This previously unknown binding mode underlies the immunodominant T cell response...
  35. ncbi H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies
    H Firat
    Unité d Immunité Cellulaire Antivirale, Département SIDA Rétrovirus, Institut Pasteur, Paris, France
    Eur J Immunol 29:3112-21. 1999
    ..Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy...
  36. ncbi HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1
    K S Lang
    Institute for Cell Biology, Eberhard Karls University, Tuebingen, Germany
    J Invest Dermatol 116:891-7. 2001
    ..The present study supports the hypothesis that vitiligo is a cytotoxic T lymphocyte-mediated autoimmune disease. The presence of melanocyte-specific reactive CD8(+) T cells seems to be closely related to disease activity...
  37. pmc Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution
    Hamid Echchakir
    Laboratoire Cytokines et Immunologie des Tumeurs Humaines, U487 Institut National de la Santé et de la Recherche Médicale, Institut Gustave Roussy, Institut Fédératif de Recherche 54, F 94805 Villejuif, Cedex, France
    Proc Natl Acad Sci U S A 99:9358-63. 2002
    ..Our results point to the existence of distinct but overlapping antitumor TCR repertoires in TIL and PBL and suggest a selective in situ expansion of tumor-specific cytotoxic T lymphocyte with high avidity/tumor reactivity...
  38. ncbi Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide
    M V Peshwa
    Dendreon Corporation, Mountain View, California 94043, USA
    Prostate 36:129-38. 1998
    ..Particularly, CD8+ T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors...
  39. ncbi Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue
    Andrew I Webb
    Protein Crystallography Unit and Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia
    J Biol Chem 279:23438-46. 2004
    ..Therefore, this approach has yielded a potential therapeutic molecule that satiates the hydrophobic F pocket of HLA A2 and exhibited superior immunogenicity relative to the wild type peptide...
  40. ncbi Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens
    Lydie Trautmann
    INSERM U463, Institut de Biologie, Nantes, France
    Eur J Immunol 32:3181-90. 2002
    ..The V alpha dominance, which may be a frequent feature of antigen-specific T cells, likely reflects a restricted geometry of TCR/peptide/MHC complexes, primarily determined by V alpha CDR...
  41. ncbi Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity
    Danila Valmori
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, and Multidisciplinary Oncology Center, University Hospital, Lausanne, Switzerland
    J Immunol 168:4231-40. 2002
    ..Collectively, these data show that tumor peptide-driven immune stimulation leads to the selection of high-avidity T cell clones of increased tumor reactivity that independently evolve within oligoclonal populations...
  42. ncbi Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen
    Pierre Yves Dietrich
    Division of Oncology, Laboratory of Tumor Immunology, University Hospital, Geneva, Switzerland
    J Immunol 170:5103-9. 2003
    ..1-bearing TCRs, whereas functional outcomes result from the sum of these with other interactions between pMHC complex and TCR...
  43. pmc Hepatitis C virus mutation affects proteasomal epitope processing
    Ulrike Seifert
    Institute of Biochemistry, Charite, Humboldt University, Berlin, Germany
    J Clin Invest 114:250-9. 2004
    ....
  44. ncbi Assembly, specific binding, and crystallization of a human TCR-alphabeta with an antigenic Tax peptide from human T lymphotropic virus type 1 and the class I MHC molecule HLA-A2
    D N Garboczi
    Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA
    J Immunol 157:5403-10. 1996
    ..Crystals of the TCR/peptide/HLA-A2 complex diffract x-rays, providing the means to study in atomic detail the mechanism of Ag-specific cell-cell recognition between T cells and target cells...
  45. pmc Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy
    T A Colella
    Department of Microbiology and the Beirne Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia 22908, USA
    J Exp Med 191:1221-32. 2000
    ..The relevance of this model to an understanding of the human immune response to tyrosinase is discussed...
  46. ncbi HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes
    B Seliger
    Third Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany
    Int J Cancer 87:349-59. 2000
    ....
  47. pmc Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice
    Lior Carmon
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    J Clin Invest 110:453-62. 2002
    ..These peptides therefore represent naturally processed BA46-derived CTL epitopes that can be used in peptide-based antitumor vaccines...
  48. ncbi A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia
    J J Molldrem
    Blood and Marrow Transplant Department, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Cancer Res 59:2675-81. 1999
    ..These results show that a PR1-HLA-A2 tetramer can be used to identify and select CTLs from normal donors that preferentially lyse CML cells, which could be used for leukemia-specific adoptive immunotherapy...
  49. ncbi A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
    T Wolfel
    Medizinische Klinik und Poliklinik, Johannes Gutenberg Universitat, Mainz, Germany
    Science 269:1281-4. 1995
    ..These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a...
  50. ncbi Molecular basis of T cell-mediated recognition of pancreatic cancer cells
    M Ito
    Department of Immunology, Kurume University School of Medicine, Japan
    Cancer Res 61:2038-46. 2001
    ..These results should provide a scientific basis for the development of specific immunotherapy for pancreatic and colon cancer patients...
  51. ncbi Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires
    P Y Dietrich
    Division of Oncology, University Hospital, Geneva, Switzerland
    Cancer Res 61:2047-54. 2001
    ..In contrast to previously characterized CD8+ T-cell responses to viral infections, this study provides evidence against usage of highly restricted TCR repertoire in the natural response to a self-differentiation tumor antigen...
  52. ncbi T cell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surface
    J Buslepp
    Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA
    J Biol Chem 276:47320-8. 2001
    ..However, contrary to previous studies, we see similar half-lives for the pMHC multimers bound to the AHIII12.2 cell surface...
  53. ncbi Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts
    A K Sharma
    Departments of Microbiology, The Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    J Biol Chem 276:21443-9. 2001
    ..Thus, it is clear that subtle changes in the identity of anchor residues may have significant effects on the positions of the T cell receptor contact residues...
  54. ncbi T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein
    L H Butterfield
    Division of Surgical Oncology, Department of Chemistry and Biochemistry, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA
    J Immunol 166:5300-8. 2001
    ....
  55. ncbi Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes
    P Sliz
    Department of Molecular and Cellular Biology and Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA
    J Immunol 167:3276-84. 2001
    ..The structures suggest both how the wild-type peptides would bind and how three categories of cytotoxic T lymphocytes with differing fine specificity might recognize the two peptides...
  56. ncbi Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells
    Jean Francois Fonteneau
    School of Medicine, New York University, New York, NY 10016, USA
    Blood 102:4448-55. 2003
    ..Altogether, these data suggest that antigens derived from apoptotic and necrotic cells require access to the cytosol to intersect with the conventional MHC class I pathway for presentation of cytosolic proteins...
  57. ncbi Direct visualization of antigen-specific T cells using peptide-MHC-class I tetrameric complexes
    Norbert Meidenbauer
    Department of Hematology and Oncology, University of Regensburg, D 93053 Regensburg, Germany
    Methods 31:160-71. 2003
    ..Recently, various technical peculiarities of tetramers have led to modifications within this important immunoassay. The current manuscript details potential pitfalls and provides guidance for interpretation of results...
  58. ncbi Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1
    Elke Jager
    Medizinische Klinik II, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Int J Cancer 98:376-88. 2002
    ..Complementary analysis for TCR CDR3 and cytokine profiles may be useful to define the most effective CD8+ T-cell population induced by peptide vaccination...
  59. ncbi Dominant TCR-alpha requirements for a self antigen recognition in humans
    Stefania Mantovani
    Laboratory of Experimental Immunology, Instituto di Ricovero e Cura a Carattere Scientifico Salvatore Maugeri Foundation, Pavia, Italy
    J Immunol 169:6253-60. 2002
    ..Our data demonstrate a dominant function of TCRAV2 segment in forming the TCR repertoire specific for the human self Ag Melan-A/MART-1 and support the view that Ag recognition is mediated predominantly by TCR-alpha...
  60. pmc The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
    V Brichard
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium
    J Exp Med 178:489-95. 1993
    ..But possible adverse effects of antityrosinase immunization, such as the destruction of normal melanocytes and its consequences, will have to be examined before clinical pilot studies can be undertaken...
  61. ncbi A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex
    X N Xu
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, OX3 9DS, Oxford, United Kingdom
    Immunity 14:591-602. 2001
    ..The ability to divorce these events may allow the deletion of antigen-specific and pathological CTL populations without the deleterious effects induced by full CTL activation...
  62. ncbi A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry
    S Pascolo
    Institut for Cell Biology, Department Immunology, University of Tubingen, Auf der Morgenstelle 15, 72076 Tubingen, Germany
    Cancer Res 61:4072-7. 2001
    ....
  63. ncbi CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes
    Roberto Mallone
    INSERM U580, Hopital Necker, 161 rue de Sevres, 75743 Paris Cedex 15, France
    Diabetes 56:613-21. 2007
    ..Combination of CD8+ T-cell measurements with immune intervention strategies may open new avenues toward type 1 diabetes prediction and prevention...
  64. ncbi Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient
    Susanna Mandruzzato
    Department of Oncology, University of Padova, Padova, Italy
    J Immunol 169:4017-24. 2002
    ..Taken together, these results buttress the notion that the CTLs recognizing the immunodominant Ag of Melan-A comprise a high number of different clonotypic TCR, of which only some exhibit common features in the CDR3...
  65. ncbi Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses
    Junichi Eguchi
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, USA
    Cancer Res 66:5883-91. 2006
    ..These findings indicate highly immunogenic IL-13Ralpha2 peptide analogues may be useful for the development of vaccines capable of effectively expanding IL-13Ralpha2-specific, tumor-reactive CTLs in glioma patients...
  66. ncbi Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide
    J J Kuhns
    Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    J Biol Chem 274:36422-7. 1999
    ..The crystallographic structure shows that unlike other class I-peptide structures, the center of the peptide does not assume one specific conformation and does not make stabilizing contacts with the peptide-binding cleft...
  67. ncbi Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376
    D Valmori
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University of Lausanne, Switzerland
    Cancer Res 59:4050-5. 1999
    ..Taken together, these findings emphasize the significant contribution of the natural tyrosinase peptide 368-376 to the antigenic specificities recognized by the tumor-reactive CTLs that may develop in HLA-A2 melanoma patients...
  68. pmc A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
    P G Coulie
    Ludwig Institute for Cancer Research, Brussels, Belgium
    J Exp Med 180:35-42. 1994
    ..The gene, designated Melan-A, is unrelated to any known gene. It is 18 kb long and comprises five exons. Like the tyrosinase gene, it is expressed in most melanoma tumor samples and, among normal cells, only in melanocytes...
  69. ncbi Characterization of an in situ IFN-gamma ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization
    D M McKinney
    Epimmune Inc, 5820 Nancy Ridge, Suite 100, San Diego, CA 92121, USA
    J Immunol Methods 237:105-17. 2000
    ..This data demonstrates that a single intramuscular administration of a DNA vaccine can induce T-cell responses that can be detected in freshly isolated splenocytes...
  70. ncbi Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients
    Christian Maczek
    Department of Dermatology, University Hospital of Erlangen Nuremberg, Erlangen, Germany
    Int J Cancer 115:450-5. 2005
    ....
  71. pmc Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells
    Jeffrey J Molldrem
    Section of Transplantation Immunology, Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 111:639-47. 2003
    ..These results provide evidence that CML shapes the host immune response and that leukemia outgrowth may result in part from leukemia-induced selective deletion of high-avidity PR1-specific T cells...
  72. ncbi Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization
    J K Sandberg
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, 171 77, Sweden
    Virology 273:112-9. 2000
    ..Three Nef regions (16-35, 106-125, and 166-185) dominated the T helper cell proliferation. The implications of these results for the development of DNA-based vaccines against HIV is discussed...
  73. pmc Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers
    X S He
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 96:5692-7. 1999
    ..Direct quantitation and characterization of HCV-specific CTLs should extend our understanding of the immunopathogenesis and the mechanism of clearance or persistence of HCV...
  74. ncbi Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy
    Monique Gannage
    Institut National de la Santé et de la Recherche Médicale INSERM Equipe Avenir, Unité 561, Hopital St Vincent de Paul, Paris, France
    J Immunol 174:8210-8. 2005
    ....
  75. ncbi Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope
    Astrid K N Iversen
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9AD, UK
    Nat Immunol 7:179-89. 2006
    ..Thus, viral escape from CTL responses does not necessarily correlate with disease progression...
  76. pmc Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
    Y Kawakami
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 91:3515-9. 1994
    ..Identification of this gene opens possibilities for the development of immunotherapies for patients with melanoma...
  77. pmc Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene
    Annika C Karlsson
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
    J Virol 77:6743-52. 2003
    ..Our results indicate that both HIV type 1-specific CD8(+) T cells and antiretroviral drugs provide complex pressures on the same amino acid sequence of the HIV protease gene and, thus, can influence viral sequence evolution...
  78. ncbi High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival
    V Karanikas
    Cellular Genetics Unit, , B-1200 Brussels, Belgium
    Cancer Res 61:3718-24. 2001
    ..These results indicate that nonmelanoma cancer patients may also have a high frequency of blood CTLs directed against a tumor-specific antigen...
  79. pmc Human leucocyte antigen-A2 restricted and Mycobacterium tuberculosis 19-kDa antigen-specific CD8+ T-cell responses are oligoclonal and exhibit a T-cell cytotoxic type 2 response cytokine-secretion pattern
    H Hohn
    Institute for Medical Microbiology, University of Mainz, Hochhaus Augustusplatz, Mainz, Germany
    Immunology 104:278-88. 2001
    ..Permutation of this T-cell epitope may aid to elicit a qualitatively different CD8+ T-cell response in patients with M. tuberculosis infection...
  80. ncbi Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases
    M J Pittet
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland
    J Immunol 166:7634-40. 2001
    ..Thus, the high sensitivity of the assay provides a valuable tool to monitor effector T cell responses in different clinical situations...
  81. ncbi Distinct molecular mechanisms account for the specificity of two different T-cell receptors
    Nadja Anikeeva
    Department of Microbiology and Immunology and Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Biochemistry 42:4709-16. 2003
    ..The use of these different mechanisms by TCRs to recognize ligands might be an important means augmenting their inherent cross-reactivity...
  82. ncbi Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region
    Mirjam H M Heemskerk
    Department of Hematology, Leiden University Medical Center, C2 R, PO Box 9600, 2300 RC Leiden, The Netherlands
    Blood 102:3530-40. 2003
    ....
  83. ncbi Coreceptor CD8-driven modulation of T cell antigen receptor specificity
    Hugo A van den Berg
    Warwick Systems Biology Centre, Coventry House, University of Warwick, Coventry CV4 7AL, UK
    J Theor Biol 249:395-408. 2007
    ..The functional diversity of the TCR repertoire would therefore be greatly augmented by coreceptor-mediated ligand focussing...
  84. ncbi Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells
    A M Asemissen
    Medizinische Klinik III, Hematology, Oncology and Transfusion Medicine, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany
    J Immunol Methods 251:101-8. 2001
    ..This comparative study shows the suitability of the determination of frequencies of antigen reactive T cells in PBMC by IC-FC. The advantage of IC-FC is the possibility to phenotype simultaneously antigen-reactive T cells...
  85. ncbi CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences
    P Romero
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Centre Hospitalier Universitaire Vaudois, Switzerland
    Clin Cancer Res 7:766s-772s. 2001
    ..The findings reported here have significant implications for the formulation of NY-ESO-1-based vaccines as well as for the monitoring of either natural or vaccine-induced NY-ESO-1-specific CTL responses in cancer patients...
  86. ncbi Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
    J J Lewis
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Cancer 87:391-8. 2000
    ..1/2,000 in the second patient. These results demonstrate that modest expansion of peptide-specific CD8(+) T cells can be generated in vivo by immunization with peptide plus QS-21 in at least a subset of patients with melanoma...
  87. ncbi Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients
    Dirk Nagorsen
    Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, University Hospital Benjamin Franklin, Berlin, Germany
    Int J Cancer 105:221-5. 2003
    ..The findings reported here have implications for the development of antigen-specific T-cell therapies...
  88. ncbi Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex
    Agapito Castilleja
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol 169:3545-54. 2002
    ....
  89. ncbi Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT
    Dih Yih Chen
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 6:1991-6. 2007
    ..Thus, I540-specific T cells can vary in cytotoxic potential depending on the method of generation, isolation and expansion...
  90. ncbi Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells
    Jiang Xiaobing
    Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Cancer Biother Radiopharm 22:826-35. 2007
    ..The aim of this study was to investigate the novel approach for targeting malignant glioma...
  91. ncbi In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins
    Tadao Asai
    University of Pittsburgh Cancer Institute, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Immun 2:3. 2002
    ....
  92. ncbi Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL
    Verena Rubio-Godoy
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland
    J Immunol 169:5696-707. 2002
    ..Together, these results underline the high predictive value of PS-SCL for the identification of sequences cross-recognized by Ag-specific T cells...
  93. pmc LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer
    Armin Bender
    Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 7:16. 2007
    ..A specific immune response of high magnitude and early onset may be more effective in eliminating minimal residual disease in adjuvant treatment situations and in preventing tumor progression due to immune escape mechanisms...
  94. ncbi Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope
    R S Andersen
    Leukemia 22:668-9. 2008
  95. ncbi Celiac disease association with CD8+ T cell responses: identification of a novel gliadin-derived HLA-A2-restricted epitope
    Carmen Gianfrani
    Institute of Food Science and Technology, Consiglio Nazionale delle Ricerche, Avellino, Italy
    J Immunol 170:2719-26. 2003
    ..Finally, we speculate on a possible mechanism leading to processing and presentation of class I-restricted gliadin-derived epitopes in celiac disease patients...
  96. ncbi Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies
    Stephen Gottschalk
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Departments of Pediatrics, Medicine, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 101:1905-12. 2003
    ..Targeting LMP1 in these malignancies may improve the efficacy of current adoptive immunotherapy approaches...
  97. ncbi Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells
    Susanne M Schmidt
    Department of Hematology, Oncology and Immunology, University of Tubingen, Germany
    Blood 102:571-6. 2003
    ..Our results demonstrate that survivin epitopes are presented on a broad variety of malignancies and can be applied in vaccination therapies...
  98. ncbi The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides
    Xiu Min Zhang
    State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Shaanxi Province 710032, P R China
    Oncol Rep 20:245-52. 2008
    ..In addition, the peptide-specific activity was observed to be in an MHC-restricted manner. Our study indicated that the combination of several tumor antigen-derived peptides may present a better peptide-based cancer immunotherapy...
  99. ncbi Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer
    James L Murray
    Department of Bioimmunotherapy, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3407-18. 2002
    ..These results demonstrate that vaccination with E75+ granulocyte macrophage colony-stimulating factor can induce both peptide-specific IFN-gamma and epitope specific CTLs, which lyse HER-2/neu+ tumors in stage IV patients...
  100. ncbi Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma
    Pedro Romero
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital CHUV, Lausanne, Switzerland
    Immunol Rev 188:81-96. 2002
    ....
  101. ncbi The use of HLA class I tetramers to design a vaccination strategy for melanoma patients
    Michael Palmowski
    Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
    Immunol Rev 188:155-63. 2002
    ..These results provide important pointers for future vaccination trials, and tetramers will form an important tool in the immunomonitoring of these clinical studies...

Research Grants65

  1. Crossprotective CTL Against Influenza
    Ellis L Reinherz; Fiscal Year: 2013
    ..It has general application to other highly mutable viral pathogens affecting mankind. ..
  2. Use of Allogenicity to Stimulate Effector Responses Against Multiple Myeloma
    Christina N Johnson; Fiscal Year: 2013
    ..Ultimately, this project seeks to contribute to the knowledge base currently being used to develop immunotherapies for diseases such as MM, specifically in populations which demonstrate well-documented health disparities. ..
  3. Development & Characterization of Tyrosinase Epitope Specific TCR Transgenic Mice
    Shikhar Mehrotra; Fiscal Year: 2010
    ..Successful completion of this proposal would provide us information about the feasibility of using this TIL1383i TCR in T cell adoptive immunotherapy protocols. ..
  4. Combination immunotherapy with gene modified CD4 and CD8 T cells and stem cells
    Carl H June; Fiscal Year: 2013
    ....
  5. Ruth L. Kirschstein National Research Service Awards for Individual Postdoctoral
    Ann F Cheung; Fiscal Year: 2010
    ..Tumor antigens serve as potential targets for cancer immune therapy, while the T cell receptors form the basis of the actual treatment. ..
  6. Specificity of CD8 cells in islets from type 1 diabetes patients
    Matthias G Von Herrath; Fiscal Year: 2013
    ..This research will expand our knowledge on how the disease is triggered in susceptible individuals and on how we may therapeutically target these cells in order to restore tolerance. ..
  7. Paraptosis induction by BK channel activation to improve glioma cancer therapy
    Martin R Jadus; Fiscal Year: 2013
    ..The potential for immediate clinical application is therefore significant. ..
  8. Immunoregulation and immunotherapy of breast cancer
    Robert H Vonderheide; Fiscal Year: 2012
    ..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..
  9. Oxidative stress and AICD in memory T cell persistence
    Shikhar Mehrotra; Fiscal Year: 2013
    ..We believe that successful completion of the proposed work would help identify targets that could be used to improve survival of effector CTL and long-term memory development in patients receiving adoptive T cell therapy for cancer. ..
  10. Dendritic Cell Vaccine Targeting Melanoma-Associated Antigens in Malignant Glioma
    Linda M Liau; Fiscal Year: 2010
    ..Thus, this is a truly bi-directional translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  11. ANTIGENIC DETERMINANTS ON HLA-B7 AND -A2
    Victor H Engelhard; Fiscal Year: 2012
    ..The goal of this proposal is to establish this relationship more directly, and to test one of these antigens for its ability to stimulate a cancer specific immune response in melanoma patients. ..
  12. Diabetogenic Role of MHC Class I Alleles in NOD Mice
    David V Serreze; Fiscal Year: 2013
    ..Such information may ultimately identify means that can attenuate the development of similar autoreactive T lymphocytes contributing to T1D in human patients. ..
  13. Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature
    Walter J Storkus; Fiscal Year: 2013
    ....
  14. Bifunctional T cell receptor based immunotherapeutics
    Hing C Wong; Fiscal Year: 2011
    ..This may lead to a safe and effective approach to treat patients with refractory, metastatic cancer. ..
  15. Cellular Immunity to JC Virus in AIDS-Associated Progressive Multifocal Leukoence
    Igor J Koralnik; Fiscal Year: 2010
    ..Aim 4) Determine the potential of JCV mRNA-transfected DC as therapeutic vaccines for PML ..
  16. Molecular mechanism of immune evasion by the E3-19K protein of Adenovirus
    Marlene Bouvier; Fiscal Year: 2012
    ..Our findings are also expected to be relevant to understand establishment and maintenance of Ad infection in healthy individuals, and disease development in immunocompromised hosts. ..
  17. Towards a Vaccine to Prevent Toxoplasmosis
    Rima L McLeod; Fiscal Year: 2012
    ..This work will provide a foundation to develop a vaccine protective against toxoplasmosis for humans as well as a paradigm for vaccines to protect against other pathogens. ..
  18. Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine
    Don J Diamond; Fiscal Year: 2013
    ..Success with this CMV vaccine would have a significant clinical and cost-saving effect on recipient management after MRD or URD HCT. ..
  19. Modeling HTLV-1 infection and cellular immune response in HLA-A2-transgenic mice
    Zafar K Khan; Fiscal Year: 2012
    ..Additionally the results of these studies will shed light on the dynamics of immune cell interactions during chronic viral infections such as HTLV-1, HIV-1, hepatitis virus and herpes simplex virus. ..
  20. TCR Engineered CD4 Cells as Helpers in Tumor Immunity
    Bijay Mukherji; Fiscal Year: 2012
    ....
  21. Immune tolerance in humanized translational models to cure diabetes
    Brian T Fife; Fiscal Year: 2013
    ....
  22. Androgen receptor targeted vaccines for prostate cancer
    Douglas G McNeel; Fiscal Year: 2013
    ....
  23. Development of Novel Chagas Vaccines
    Daniel F Hoft; Fiscal Year: 2013
    ..The outcome of our studies will provide key data required for proceeding with phase I Chagas vaccine trials. ..
  24. Engineering High-Affinity T Cell Receptors Against Cancer Antigens
    Daniel Harris; Fiscal Year: 2013
    ..This aim will develop an optimal scaffold library so that rapid isolation of high-affinity TCRs can be achieved, facilitating their use in adoptive T cell immunotherapies for diverse cancers and many more patients. ..
  25. Papillomavirus Host Interation
    Neil D Christensen; Fiscal Year: 2013
    ..The goal of this research project is to optimize approaches to induce immunotherapeutic T-cell immune responses that can eliminate existing HPV infections and associated cancers. ..
  26. Phase I Study of ALT-801 in Metastatic Melanoma/Kidney Cancer Patients
    Mayer Fishman; Fiscal Year: 2009
    ....
  27. Optimization of Tumor Vaccines for the Aged
    Sandra J Gendler; Fiscal Year: 2013
    ..The information of these studies will reveal new strategies for controlling and manipulating the immune system to develop more effective cancer-immunotherapies in old tolerant hosts. ..
  28. Optimizing Gag CTL Epitopes to Improve Immunogenicity
    June Kan Mitchell; Fiscal Year: 2010
    ..A new approach, combining studies of the TCR degeneracy for SL9 and TV9 with reverse genetics, will be tested to improve the immunogenicity of HIV Gag. ..
  29. HLA-RELEASING METALLOPROTEINASE IN ALLOGRAFT REJECTION
    Yuri Bushkin; Fiscal Year: 2009
    ..abstract_text> ..
  30. Antigen processing and HLA-peptide complexes in head and neck cancer
    Soldano Ferrone; Fiscal Year: 2010
    ..abstract_text> ..
  31. Biophysical analysis of T-cell discrimination among classes of self-ligands
    Michelle Krogsgaard; Fiscal Year: 2010
    ..Alternatively, soluble TCRs with well-defined specificities could also be modified to deliver radionuclides, toxins or immunomodulatory molecules for more efficient killing of tumor cells. ..
  32. Ocular Mucosal Immunity Induced by HSV-1 Lipopeptide
    Lbachir BenMohamed; Fiscal Year: 2013
    ....
  33. Antigens Recognized by CD8+ T Cells in Type 1 Diabetes
    Teresa P DiLorenzo; Fiscal Year: 2013
    ....
  34. Modulating tolerance in a spontaneous mouse model of autoimmune vitiligo
    ISABELLE CAROLINE LE POOLE; Fiscal Year: 2013
    ....
  35. Innate and Adaptive Immune Responses in Pre-type 1 Diabetes
    Kevan C Herold; Fiscal Year: 2010
    ..We are requesting samples from autoantibody relatives of patients who do and do not progress to diabetes. ..
  36. Immunotherapy after ASCT for MM Using hTERT Vaccination + Vaccine-primed T cells
    Aaron Rapoport; Fiscal Year: 2009
    ..AIM 2: To assay for development of cellular immune responses to the hTERT multi-peptide vaccine in the cohort of HLA A2+ patients who receive the combination of the multi-peptide vaccine and the vaccine-primed and costimulated T-cells. ..
  37. Defining T cell epitopes in Dengue virus infection
    Ramila Philip; Fiscal Year: 2013
    ....
  38. CONFERENCE--ISOLATED FETAL CELLS IN MATERNAL BLOOD
    Joe Simpson; Fiscal Year: 1993
    ....
  39. CATALASE IMMUNITY IN PRIMARY SCLEROSING CHOLANGITIS
    James Versalovic; Fiscal Year: 2005
    ..The proposed animal model will facilitate the evaluation of diagnostic and therapeutic strategies for PSC in vivo. ..
  40. RNAi manipulations of DC to enhance HIV immunogenicity
    Premlata Shankar; Fiscal Year: 2013
    ..In Aim 3, we will validate the in vitro findings as well as test the efficacy of our methods to actually confer protection from in vivo HIV challenge in the humanized BLT mouse model transgenic for HLA-A2 and HLA-B27. ..
  41. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..Blood, marrow and skin biopsy samples will be obtained for correlative studies relating to immune reconstitution and minimal residual disease and compared with historical controls. ..
  42. Soluble TCR-IL15 Fusions as Targeted Therapeutics for Cancer
    Peter Rhode; Fiscal Year: 2009
    ..Ultimately, this approach may provide a safer and more effective treatment for patients with cancer than the currently approved immunotherapies. ..
  43. Listeria Immunotherapy for Pancreatic and Ovarian Cancer
    Thomas Dubensky; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  44. Allergy Prevention By lgE Cytotoxic Peptide(ECP)Vaccine
    Swey Shen Chen; Fiscal Year: 2002
    ....
  45. PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA
    Jeffrey Molldrem; Fiscal Year: 2002
    ..Lastly, other synthetic HLA-A2-associated peptides from Pr3 will be investigated for their potential to elicit peptide-specific CTL from donor PBMC in vitro and then tested for ability to lyse myeloid leukemia. ..
  46. M Tuberculosis CTL Epitopes: Vaccine Design/Evaluation
    Elizabeth Mellins; Fiscal Year: 2007
    ..For TB, which takes years to decades to develop after infection with Mtb, immune correlates with protection are an attractive, and perhaps essential, supplement to efficacy trials. ..
  47. PATHOGENESIS OF POST-TRANSPLANT BRONCHIOLITIS OBLITERANS
    Thalachallour Mohanakumar; Fiscal Year: 2004
    ..The overall goal of this proposal is to employ this unique murine preclinical model of OAD in order to define the cellular and molecular mechanism leading to BOS following clinical lung transplantation. ..
  48. T CELL IMMUNE RESPONSE TO BREAST CARCINOMA
    Timothy Eberlein; Fiscal Year: 1999
    ..These CTL could be used in adoptive immunotherapy of cancer patients. Finally, synthetic tumor-derived peptides could be used in a vaccine-based treatment of patients with cancer. ..
  49. DEVELOPING T CELLS CLONES CYTOTOXIC TO SARCOMAS
    Michael Mastrangelo; Fiscal Year: 1990
    ..It is hoped that these studies will lead to a better understanding of the biology of sarcomas and provide reagents for clinical trials...
  50. PEPTIDE-PULSED DENDRITIC CELL THERAPY FOR MELANOMA
    Frank Haluska; Fiscal Year: 2000
    ..Our final objective is the comparison of immunologic data obtained from the two trials. ..
  51. CHEMOKINES IN CTL FUNCTION AND TRAFFICKING IN HIV
    Andrew Luster; Fiscal Year: 2004
    ..abstract_text> ..
  52. ANTIGENIC DETERMINENTS ON HLA-B7 AND HLA-A2
    VICTOR ENGELHARD; Fiscal Year: 2001
    ....
  53. RECOGNITION OF HLA-A2 MOLECULE BY HUMAN CYTOTOXIC T CELL
    Craig Hall; Fiscal Year: 1992
    ..The latter goal take s impetus from the recently published crystal structure of the HLA-A2 molecule...
  54. Dev. of Optimized/Adjuvanted Smallpox DNA Vaccine (Gene Gun)
    T C Wu; Fiscal Year: 2009
    ..The successful implementation of the proposed studies will result in an improved poxvirus DNA vaccine potentially suitable for clinical development. ..
  55. Rational Design of Therapeutic Vaccines for CEA+ Tumors
    SUNIL CHATTERJEE; Fiscal Year: 2007
    ..The results obtained from these studies will help design improved therapeutic vaccines for the treatment of CEA+ tumors and can be incorporated readily into our ongoing clinical programs. ..
  56. Regulation of Class I Gene Expressions in Tumor Cells
    GORDON GINDER; Fiscal Year: 2005
    ....
  57. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
  58. TCR Transduction for EBV Specific Immunotherapy
    Rimas Orentas; Fiscal Year: 2004
    ..With a better understanding of these first principles of functional ICR assembly in primary lymphocytes, other malignancies with known tumor-associated antigens could be targeted by this approach as well. ..
  59. CTL DEFINED ANTIGENS IN NON SMALL CELL LUNG CANCER
    John Yannelli; Fiscal Year: 2001
    ..These attempts to generate specific CTL in NSCLC will add greatly to our knowledge base of the immunological response to this disease as well as provide critical reagents for vaccine or cellular immunotherapy protocols. ..
  60. Novel targets for vaccines against tuberculosis
    Yuri Bushkin; Fiscal Year: 2006
    ..This knowledge is expected to open a new approach in designs of vaccines against M. tuberculosis. [unreadable] [unreadable]..
  61. Vaccine with altered HIV antigens
    Danuta Kozbor; Fiscal Year: 2003
    ..III) We will analyze protection levels achieved by DNA immunization with the modified Gag-Pol fusion constructs against intrarectal challenge with rVV expressing Gag and Pol proteins. ..
  62. Modeling Human MHC Class I Diabetes Functions in Mice
    Michele Marron; Fiscal Year: 2005
    ..Thus, my second specific aim is to determine if the range of diabetogenic CD8 T cell clonotypes elicited by transgenic expression of HLA-A24 molecules is more diverse than that elicited by HLA-A2.1 molecules. ..
  63. Therapeutic Effectiveness of T Cell Receptor mimic (TCRm) Antibodies in Breast Ca
    Jon Weidanz; Fiscal Year: 2009
    ..Completion of these studies is expected to lead to development of new therapeutic antibodies for the treatment of breast cancer. ..
  64. POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA
    Jean Claude Bystryn; Fiscal Year: 2004
    ..More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases. ..
  65. LENTIVIRUS TRANSDUCED DENDRITIC CELLS FOR HIV VACCINES
    June Kan Mitchell; Fiscal Year: 1999
    ..For proof of concept of in vivo transduction, the investigators will immunize mice in vivo with the vector, after daily injections of FL designed to dramatically increase the number of DC precursors in vivo. ..